Foghorn Therapeutics (FHTX) Gains from Investment Securities (2020)
Foghorn Therapeutics' (FHTX) quarterly Gains from Investment Securities came in at $70000.0 in Q3 2020, up 7100.0% quarter-over-quarter from -$1000.0 in Q1 2020.
Foghorn Therapeutics (FHTX) Gains from Investment Securities (2020) Analysis & Trends
Foghorn Therapeutics' Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $70000.0 for Q3 2020.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $70000.0 in Q3 2020; TTM through Jun 2021 was $70000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $69000.0, up 7000.0% from the prior year.
- Gains from Investment Securities rose to $70000.0 in Q3 2020 per FHTX's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $70000.0 in Q3 2020 and bottomed at -$1000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Foghorn Therapeutics | 355.35 Mn | 266.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 70,000.00 |
| Sep 30, 2020 | 70,000.00 |
| Mar 31, 2020 | -1,000.00 |
| Mar 31, 2020 | -1,000.00 |